Clinical Research Directory
Browse clinical research sites, groups, and studies.
Paclitaxel Polymeric Micelles and Carboplatin in Combination With Iparomilimab and Tuvonralimab Neoadjuvant Therapy for Triple-negative Breast Cancer
Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Summary
This is a prospective, single-arm, multicenter study to observe and evaluate the efficacy and safety of paclitaxel polymeric micelles and carboplatin in combination with iparomilimab and tuvonralimab in neoadjuvant therapy for triple-negative breast cancer. The main endpoint of the study is pCR, 32 patients are scheduled to be enrolled.
Key Details
Gender
FEMALE
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
32
Start Date
2025-04-02
Completion Date
2028-10-01
Last Updated
2025-04-04
Healthy Volunteers
No
Interventions
paclitaxel polymeric micelles + carboplatin + iparomilimab and tuvonralimab
paclitaxel polymeric micelles 300mg/m2, d1 carboplatin AUC=5, d1 iparomilimab and tuvonralimab 5mg/kg, d1 Every 3 weeks (Q3W) is a cycle, a total of 6 cycles.
Locations (1)
Cancer Hospital, Chinese Academy of Medical Sciences
Beijing, China